OAG
ALNY icon

Orbis Allan Gray’s Alnylam Pharmaceuticals ALNY Stock Holding History

Orbis Allan Gray’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$598M Buy
1,987,407
+652,582
+49% +$197M 2.06% 15
2026
Q1 		$442M Sell
1,334,825
-283,394
-18% -$96.4M 1.86% 19
2025
Q4 		$643M Sell
1,618,219
-332,743
-17% -$147M 2.7% 9
2025
Q3 		$890M Sell
1,950,962
-170,450
-8% -$69.4M 3.82% 5
2025
Q2 		$692M Buy
2,121,412
+486,489
+30% +$135M 3.36% 6
2025
Q1 		$441M Buy
1,634,923
+162,121
+11% +$41.7M 2.53% 11
2024
Q4 		$347M Buy
1,472,802
+204,690
+16% +$53.8M 1.86% 18
2024
Q3 		$349M Buy
1,268,112
+547,059
+76% +$142M 1.85% 19
2024
Q2 		$175M Buy
+721,053
New +$114M 1.09% 33
2023
Q4 		– Sell
-38,189
Closed -$6.76M – 74
2023
Q3 		$6.76M Buy
+38,189
New +$7.29M 0.05% 71

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Orbis Allan Gray's ALNY Position: Q2 2026 in Review

Orbis Allan Gray increased its Alnylam Pharmaceuticals (ALNY) stake by 49% in Q2 2026, buying an estimated $197M and bringing the position to 1,987,407 shares worth $598M. The position accounts for 2.06% of the portfolio, ranked #15.

Orbis Allan Gray first reported a position in ALNY in Q3 2023 and has held it in 10 quarters since. The position peaked at $890M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Orbis Allan Gray held 1,987,407 shares of Alnylam Pharmaceuticals worth $598M as of Q2 2026.
  • Orbis Allan Gray bought 652,582 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $197M.
  • Alnylam Pharmaceuticals made up 2.06% of Orbis Allan Gray's portfolio in Q2 2026, its #15 holding.
  • Orbis Allan Gray first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Orbis Allan Gray's Alnylam Pharmaceuticals position peaked at $890M in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Orbis Allan Gray's 13F filing for Q2 2026, filed 14 Aug 2026.